Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06994026
Starting soon Observational

Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis

NCT06994026 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Gonesse
Phase
Observational
Started
2025-06-15
Last updated
2025-05-29

Condition(s) studied

Multiple SclerosisDisease ManagementFeasibility Studies

Study summary

This study aims to evaluate a questionnaire used by a specialized nurse to help manage relapses in people with multiple sclerosis (MS). The questionnaire is completed during a phone call when the patient reports new or worsening symptoms. It helps the nurse decide whether further tests or treatments are needed, based on a protocol developed with a neurologist. The goal is to improve how quickly and effectively patients receive care during a relapse. The study will include 10 adult patients with active forms of MS over a two-month period.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients followed by Dr. Manchon for Relapsing-Remitting Multiple Sclerosis or active Secondary Progressive Multiple Sclerosis * Adult patients (aged 18 or older) * Patients who have provided informed consent for participation in the local task-sharing protocol Exclusion Criteria: * Pregnant women * Minors (under 18 years old) * Patients with known renal failure * Patients who have not provided or are unable to provide consent for the local task-sharing protocol

Primary outcome measure(s)

  • Effectiveness of the relapse investigation questionnaire completed by the MS care coordinator nurse (IDEC) in guiding the patient's care pathway during a suspected relapse, according to the local task-sharing protocol. — June 2025 - August 2025

Trial sites (1)

FacilityCityRegionStatus
France Gonesse France

More Centre Hospitalier de Gonesse trials in France

Screening for Cognitive Disorders in Multiple Sclerosis Starting soon
High Risk of Death or Disability in Brain Hemorrhage: Role of Spot Sign and Secondary Markers Starting soon
Eligibility of Patients Referred to Emergency Departments by Their General Practitioners for Care in Walk-in Clinics: A Single-Center Study in Île-de-France Recruiting
Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients Starting soon
Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke Recruiting

Other trials for the same condition

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis Active, not recruiting
Screening for Cognitive Disorders in Multiple Sclerosis Starting soon
How to Develop the Highest Possible Leading-edge Interdisciplinary Care Model for People With MS, That Will be Relevant to All Stakeholders and Declinable to Different Local Contexts With the Ultimate Goal of Ensuring the Highest Level of Quality of Care in MS. Recruiting
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Active, not recruiting
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06994026 on ClinicalTrials.gov ↗ ← All trials in France